Carl Weissman is senior advisor and former CEO and chairman at Accelerator, a joint investment vehicle backed by a syndicate of venture capital firms. Accelerator invests in and actively manages emerging biotechnology companies. Carl was also previously a Venture Partner at MPM Capital. While at MPM, he served as President and CEO of Centagenetix, a human genetics company in Cambridge, MA. Carl led the 2003 merger of Centagenetix with Elixir Pharmaceuticals, catalyzing a $40M Series B financing in the combined company. Prior to joining MPM, he spent six years at Prolinx, Inc., where he held a number of positions, culminating as the head of both Finance and Business Development. Carl serves on the board of the WBBA and is Vice President of the Board of Teens in Public Service.
I am apolitical by nature. The entire process of electing representatives, from city councils to Presidents, leaves me cold. Blame my extraordinary microeconomics professor H. Scott Bierman who was at Carleton... Read more »
Seattle has, from my point of view, carved out its position as the No. 3 biotech market in the U.S. behind Boston and the San Francisco Bay Area. Michigan is currently... Read more »
I am quite often asked, in some form or another, “What can [STATE][LOCAL] government do to spur on an innovation-based economy in [SEATTLE][WASHINGTON]?”
Well, as I said on a panel at... Read more »
Tell me if this makes sense to you:
—If I buy a diamond, I can own it for as long as I like;
—If I produce a brand name for a... Read more »
(Editor’s Note: Carl Weissman submitted this in response to a feature story about entrepreneur Johnny Stine, who clearly relishes building a biotech startup without venture capital.)
Stickin’ it to the... Read more »
I guess when you are Sequoia, you can hold a big public media-attended meeting where you display a faux tombstone ominously announcing the death of the Good Times. My approach... Read more »
© 2007-2018, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.